Asston Pharmaceuticals Ltd vs Mono Pharmacare Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: Jun 14, 2026

Key Highlights

The Latest Trading Price of Asston Pharmaceuticals Ltd is ₹ 82.78 as of 12 Jun 15:30 . The P/E Ratio of Asston Pharmaceuticals Ltd is 0 as of March 2023 .The P/E Ratio of Mono Pharmacare Ltd is 0 as of March 2023 . The Market Cap of Asston Pharmaceuticals Ltd is ₹ 0 crore as of March 2023 .The Market Cap of Mono Pharmacare Ltd is ₹ 0 crore as of March 2023 . The Dividend Payout of Asston Pharmaceuticals Ltd changed from 0 % on March 2023 to 0 % on March 2022 . This represents a CAGR of 0.0% over 4 yearsThe Dividend Payout of Mono Pharmacare Ltd changed from 0 % on March 2023 to 0 % on March 2022 . This represents a CAGR of 0.0% over 4 years .

About Asston Pharmaceuticals Ltd

Asston Pharmaceuticals Limited was incorporated on 16th April 2019 as 'Asston Pharmaceutical Pvt.
Limited' to contract produce pharmaceutical products for export market.
Later on 1st April 2024, Company acquired Ferron Lifecare Private Limited, specializing into nutraceuticals business and produced nutraceutical products at their Ambarnath facility.
Ferron Lifecare Private Limited, incorporated on 30th January 2020.
Finally, 'Asston Pharmaceuticals Private Limited' was converted into a Public Limited Company in the name of 'Asston Pharmaceuticals Limited' on 29th August 2024 and received FDA approval for its Ambarnath facility on 2nd December 2024 to produce pharmaceutical products. Presently, Company is involved in the business of manufacturing and marketing of Tablets, Capsules, Oral Liquid, External Preparations (Ointment, Cream, Gel and Lotion) and Oral Powder (Sachet, Dry Syrup) etc.

About Mono Pharmacare Ltd

Mono Pharmacare Limited was originally formed as a Partnership Firm in the name and style of 'M/s.
Mono Chemist' through Partnership Deed dated May 06, 1994.
The Partnership Firm was then converted into Public Limited company in the name of Mono Pharmacare Limited vide Certificate of Incorporation dated October 17, 2022, was issued by the Registrar of Companies, Ahmedabad.
The Company is engaged in the business of marketing and distribution of pharmaceutical products. The product portfolio comprises of a wide range of drugs like Antibiotics, Antifungal, Anti CoughCold & Anti-allergic, Antacid and Antiemetics, Analgesics and Antipyretics, Nutraceuticals, Skincare, Antiseptic, Cardiac and Diabetic & Cosmetics etc. getting products manufactured through contract manufacturing. Supal Distributors LLP, a Partnership Firm, was incorporated on November 24, 2016, with the Promoters of Company, Panilam Lakhatariya and Supal Lakhatariya, being the Original Partners.

FAQs for the comparison of Asston Pharmaceuticals Ltd and Mono Pharmacare Ltd

Which company has a larger market capitalization, Asston Pharmaceuticals Ltd or Mono Pharmacare Ltd?

Market cap of Asston Pharmaceuticals Ltd is 70 Cr while Market cap of Mono Pharmacare Ltd is 20 Cr

What are the key factors driving the stock performance of Asston Pharmaceuticals Ltd and Mono Pharmacare Ltd?

The stock performance of Asston Pharmaceuticals Ltd and Mono Pharmacare Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Asston Pharmaceuticals Ltd and Mono Pharmacare Ltd?

As of June 14, 2026, the Asston Pharmaceuticals Ltd stock price is INR ₹82.78. On the other hand, Mono Pharmacare Ltd stock price is INR ₹11.65.

How do dividend payouts of Asston Pharmaceuticals Ltd and Mono Pharmacare Ltd compare?

To compare the dividend payouts of Asston Pharmaceuticals Ltd and Mono Pharmacare Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.